CTRI/2020/03/023815尚未招募未知
Efficacy of a PD-1 as an Adjunct Immunotherapy in tuberculosis patients.
Department of Biotechnology0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of 18 to 60 yrs of age; either sex.
- •2. DR-TB patients.
- •3. DS-TB patients.
排除标准
- •1.Hypersensitivity anti-TB drugs.
- •2.Presence of secondary immunodeficiency states : Organ transplantation, diabetes mellitus, malignancy, treatment with cytotoxic drugs and corticosteroids
- •4. Currently receiving cytotoxic therapy, or have received it within the last 3 months
- •5. Pregnancy and lactation.
- •6. Patients with known symptomatic cardiac disease, such as arrhythmias or coronary artery disease, marked tachypnoea, chronic cor pulmonale, congestive cardiac failure.
- •7. Patients with hematological abnormalities (WBC less than or equal to 3000/mm3; platelets less than or equal to 100,000/mm3).
- •8. Seriously ill and moribund patients with complications.
研究者
相似试验
进行中（未招募）
1 期
Administration of an anti-cancer therapy, which is based on release of brakes in the natural immune response, in patients which are planned to subsequently undergo surgery for removal of their non-small cell lung cancernon-small cell lung cancer (NSCLC), resectableMedDRA version: 20.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000105-20-DEAIO-Studien-gGmbH30
进行中（未招募）
1 期
Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resectioStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004944-37-FIMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900
进行中（未招募）
3 期
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group2023-509136-25-00Merck Sharp & Dohme LLC572
招募中
3 期
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.serious type of skin cancer caused especially by the light of the sun10040900NL-OMON56050Merck Sharp & Dohme (MSD)108
进行中（未招募）
1 期
Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resectioStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004944-37-DKMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900